PMCF Plan & Report under EU MDR 2017/745
Post-Market Clinical Follow-up is the regulatory bridge between your pre-market clinical evaluation and the real-world clinical performance of your medical device. A robust PMCF plan defines how you will proactively gather clinical data after CE marking, and the PMCF report demonstrates that your device continues to meet its intended purpose safely and effectively throughout its entire lifecycle.
What Is Post-Market Clinical Follow-up (PMCF)?
Post-Market Clinical Follow-up (PMCF) is a structured, proactive, and continuous process of collecting and evaluating clinical data on a medical device after it has been placed on the market. It is mandated under EU MDR 2017/745, Article 61(11) and further detailed in Annex XIV Part B. The purpose of PMCF is to confirm the safety and clinical performance of the device throughout its expected lifetime, to identify previously unknown risks or emerging side effects, and to ensure that the benefit-risk ratio documented in the Clinical Evaluation Report (CER) remains valid in light of real-world usage data.
Unlike routine post-market surveillance (PMS), which passively monitors complaints, vigilance reports, and field safety corrective actions, PMCF requires active, planned clinical data collection. The PMCF plan must describe specific activities designed to generate clinical evidence that addresses residual uncertainties identified during the pre-market clinical evaluation. This may include post-market clinical studies, registry-based data collection, structured surveys, or systematic literature monitoring. all tailored to the device and its risk profile.
PMCF does not exist in isolation. It forms a critical feedback loop with the clinical evaluation process. Data generated through PMCF activities must be analyzed and fed back into the CER during its periodic updates. The Clinical Evaluation Plan (CEP) should reference PMCF as a data source, and the State of the Art (SOTA) analysis should be reviewed and updated when PMCF findings reveal new clinical benchmarks or safety signals. This cyclical integration is what the MDR envisions as a living clinical evaluation system rather than a one-time documentation exercise.
PMCF vs. PMS: Understanding the Distinction
One of the most common regulatory misunderstandings is treating PMCF as synonymous with PMS. While both fall under the post-market obligations of the manufacturer, they serve different purposes and operate at different levels of specificity:
- Post-Market Surveillance (PMS) A broad, reactive system that captures complaints, incident reports, trend analyses, and field safety corrective actions. PMS is governed by MDR Articles 83–86 and feeds into the Periodic Safety Update Report (PSUR) or Post-Market Surveillance Report (PMSR).
- Post-Market Clinical Follow-up (PMCF) A focused, proactive, clinical-evidence-driven process specifically designed to answer clinical questions that remained open after the pre-market clinical evaluation. PMCF is governed by MDR Article 61(11) and Annex XIV Part B, and its findings feed directly into the CER.
A PMS system tells you what is happening in the field. PMCF tells you whether your clinical evaluation conclusions still hold. The two are complementary, but they are not interchangeable. Notified Bodies consistently flag submissions where the PMCF plan is nothing more than a repackaged PMS plan with no device-specific clinical endpoints or data collection strategy.
PMCF Plan vs. PMCF Report
The MDR requires manufacturers to prepare both a PMCF plan and a PMCF report. While these documents are closely related, they serve fundamentally different purposes within the clinical evaluation lifecycle. The PMCF plan is forward-looking: it defines what data will be collected, how, and why. The PMCF report is retrospective: it presents the data collected, analyzes it, and draws conclusions about continued device safety and performance.
| Aspect | PMCF Plan | PMCF Report |
|---|---|---|
| Purpose | Defines the strategy, methods, and objectives for proactive post-market clinical data collection | Presents the results and conclusions of executed PMCF activities |
| Key Content | Clinical questions to be answered, PMCF activity descriptions, study designs, endpoints, sample size justification, timelines, and data analysis methods | Summary of data collected, statistical analysis results, evaluation against acceptance criteria, conclusions on device safety and performance, and recommendations for CER update |
| Timing | Prepared before or at the time of CE marking and updated when clinical questions change or new gaps are identified | Prepared after PMCF data has been collected and analyzed; updated at intervals aligned with the CER update cycle |
| Regulatory Reference | MDR Annex XIV Part B, Section 1; MDCG 2020-7 (Plan Template) | MDR Annex XIV Part B, Section 2; MDCG 2020-7 (Report Template); MDCG 2020-8 (Study Evaluation Report) |
| Reviewed By | Notified Body during conformity assessment and subsequent audits | Notified Body during CER review and periodic surveillance assessments |
| Relationship to CER | Referenced in the CER as the planned approach for addressing residual clinical uncertainties identified during the clinical evaluation | Integrated into the CER update; PMCF report findings may confirm, modify, or challenge existing CER conclusions |
A common deficiency observed by Notified Bodies is the lack of coherence between the PMCF plan and the PMCF report. The plan outlines specific clinical questions and endpoints, but the report fails to address those exact questions, or vice versa. The two documents must form a logically consistent pair: the plan asks the questions, and the report answers them.
PMCF Activities: Methods for Proactive Clinical Data Collection
Annex XIV Part B of the MDR provides a non-exhaustive list of PMCF activities that manufacturers may employ. The choice of activities must be justified based on the device type, risk class, clinical questions remaining from the pre-market evaluation, and the availability of relevant data sources. Below are the most common PMCF activities recognized by Notified Bodies and regulatory authorities:
Clinical Registries
Enrollment in existing clinical registries (e.g, joint replacement registries, cardiac device registries) to collect long-term outcome data on device performance in routine clinical practice. Registry data offers large sample sizes and real-world conditions but requires data quality controls and clear endpoint definitions.
Post-Market Clinical Studies
Prospective or retrospective clinical studies designed specifically to answer PMCF clinical questions. These may include single-arm studies, comparative studies, or observational cohorts. Study protocols should follow ISO 14155 where applicable and include defined primary and secondary endpoints with statistical analysis plans.
Surveys & Questionnaires
Structured surveys distributed to healthcare professionals or patients to collect data on usability, patient-reported outcomes (PROs), satisfaction, and clinical effectiveness. Validated questionnaire instruments (e.g, EQ-5D, VAS pain scales) strengthen the credibility of collected data significantly.
Literature Monitoring
Ongoing, systematic monitoring of scientific literature for new publications relevant to the device, its intended purpose, equivalent devices, and the state of the art. This is not a one-time search but a continuous activity integrated with the periodic CER update process and documented with reproducible search strategies.
Complaint & Vigilance Analysis
While complaints and vigilance data are primarily PMS activities, their systematic clinical analysis within the context of PMCF endpoints adds value. Trending adverse event rates against pre-market predictions and literature benchmarks provides actionable PMCF data that can confirm or challenge clinical evaluation conclusions.
Real-World Data Collection
Structured collection of clinical performance data from routine use, including electronic health records (EHR), hospital discharge databases, insurance claims data, and device tracking systems. Real-world evidence (RWE) is increasingly accepted by Notified Bodies when collected with appropriate data governance and quality assurance measures.
Common PMCF Deficiencies Flagged by Notified Bodies
Notified Bodies and competent authorities routinely identify critical weaknesses in PMCF documentation during conformity assessments. Based on published MDCG guidance, Notified Body position papers, and audit experience, the following deficiencies appear most frequently:
Generic Plan Not Device-Specific
Using a boilerplate PMCF plan template that is not tailored to the specific device, its intended purpose, risk profile, or the clinical questions identified during the pre-market evaluation. Notified Bodies expect PMCF plans that clearly reference the device’s unique clinical context and residual uncertainties.
No Defined Clinical Endpoints
Failing to specify measurable clinical endpoints. both primary and secondary. that the PMCF activities are designed to evaluate. Without defined endpoints, it is impossible to assess whether PMCF data collection has achieved its objectives or whether the benefit-risk ratio has been confirmed.
Insufficient Sample Size Justification
Proposing a sample size for PMCF studies or surveys without providing a statistical rationale. The sample size must be sufficient to detect clinically meaningful differences or confirm safety at an acceptable confidence level. Notified Bodies increasingly expect formal power calculations or event rate-based justifications.
No Link to CER Conclusions
PMCF plans that exist as standalone documents without any clear connection to the residual uncertainties, evidence gaps, or open questions identified in the CER. The PMCF plan must demonstrate traceability to specific CER conclusions that require post-market confirmation or further investigation.
Treating PMCF as Just PMS
Confusing post-market surveillance with post-market clinical follow-up. Listing only passive complaint monitoring, vigilance reporting, and trend analysis as PMCF activities without including any proactive, structured clinical data collection. PMCF requires active data generation, not just passive monitoring.
Missing Study Timeline & Milestones
Presenting a PMCF plan without a clear timeline, milestones, or interim analysis points. Notified Bodies expect to see when data collection will begin, when interim analyses will be performed, and when the PMCF report will be finalized and integrated into the CER update cycle.
How We Help with Your PMCF
Dr. Hatem Rabeh and the Clinical Evaluation Navigator team provide comprehensive PMCF support, from initial plan development through study execution and report finalization. Our approach ensures that your PMCF documentation meets Notified Body expectations and integrates seamlessly with your broader clinical evaluation strategy:
- ✓ PMCF Plan Drafting Development of device-specific PMCF plans aligned with MDCG 2020-7 templates, including clear clinical questions, justified activity selection, defined endpoints, and realistic timelines tailored to your device class and risk profile
- ✓ PMCF Report Writing Comprehensive PMCF report preparation that presents collected data, performs statistical analyses, evaluates results against pre-defined acceptance criteria, and provides actionable conclusions for the CER update
- ✓ Study Design & Protocol Development Design of PMCF clinical studies compliant with ISO 14155, including protocol writing, case report form development, and statistical analysis plan preparation for prospective and retrospective study designs
- ✓ Sample Size Calculation & Statistical Planning Formal sample size justification using power analysis, event rate estimation, or precision-based approaches appropriate to the study design and the clinical questions being addressed
- ✓ Registry Identification & Enrollment Strategy Identification of relevant clinical registries for your device category, assessment of registry data quality and completeness, and development of enrollment strategies that maximize data utility
- ✓ Survey Design & Questionnaire Validation Development of structured surveys and questionnaires for healthcare professionals and patients, incorporating validated patient-reported outcome measures (PROMs) where applicable
- ✓ CER–PMCF Alignment Ensuring full traceability between your CER conclusions, identified evidence gaps, PMCF plan activities, and PMCF report findings. creating the closed-loop system that Notified Bodies expect to see
Frequently Asked Questions
What is the difference between PMCF and PMS?
Post-Market Surveillance (PMS) is a broad system for collecting and analyzing information about a medical device after it enters the market, including complaints, incidents, and trend data (MDR Articles 83–86). Post-Market Clinical Follow-up (PMCF) is a specific, proactive process within the clinical evaluation framework (MDR Article 61(11), Annex XIV Part B) designed to actively collect clinical data that addresses residual questions from the pre-market clinical evaluation. PMS is reactive and operational; PMCF is proactive and clinical. They feed into different documents. PMS into the PSUR/PMSR, and PMCF into the CER.
Is a PMCF plan required for Class I devices?
Yes. MDR Article 61(11) applies to all device classes. Even for Class I devices, the manufacturer must evaluate whether PMCF activities are necessary. If the manufacturer concludes that PMCF is not applicable, this decision must be duly justified in the clinical evaluation documentation. In practice, most Class I devices will require at least literature monitoring and some form of structured follow-up, particularly when clinical claims are made. A blanket statement that “PMCF is not needed for Class I” without supporting justification is not acceptable to Notified Bodies or competent authorities.
How does PMCF feed into the CER update?
PMCF data must be analyzed and incorporated into the CER at each update cycle. The PMCF report presents the collected clinical data and its analysis. The CER evaluator then assesses whether the PMCF findings confirm, modify, or challenge the existing clinical evaluation conclusions. If PMCF data reveals new risks, altered benefit-risk ratios, or changes in the state of the art, the CER conclusions must be updated accordingly. This feedback loop ensures that the clinical evaluation remains a living document throughout the device lifecycle.
What types of PMCF studies are accepted by Notified Bodies?
Notified Bodies accept a range of PMCF study designs, provided they are scientifically justified and appropriate for the clinical questions being addressed. Accepted designs include prospective observational studies, retrospective analyses, registry-based studies, comparative cohort studies, patient surveys using validated instruments, and systematic literature reviews. The key requirement is not the study type itself but whether it generates sufficient, high-quality clinical data to address the specific residual uncertainties identified in the CER. MDCG 2020-8 provides the template for PMCF study evaluation reports.
How often should the PMCF report be updated?
The PMCF report should be updated in alignment with the CER update cycle. For Class III devices and implantables, this means at least annually. For Class IIa and IIb devices, updates should occur at least every two to five years, or more frequently if new data warrants it. Additionally, the PMCF report should be updated whenever significant new clinical data becomes available, a safety signal is detected, or the benefit-risk profile changes. The update frequency should be defined in the PMCF plan itself.
Related Articles
Need Help with Your PMCF?
Join the Clinical Evaluation Navigator community to get expert guidance on PMCF plan development, study design, sample size justification, and PMCF report writing. Ask questions directly to Dr. Hatem Rabeh and connect with regulatory professionals navigating the same challenges.
Free to join • Weekly expert calls • 200+ published articles
